Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: There are limited data about the influence of the central nervous system (CNS) involvement on the prognosis for patients with the Asian variant of intravascular large B-cell lymphoma (IVLBCL). Methods: We analyzed 46 patients who were diagnosed with IVLBCL between 2001 and 2018. All patients were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Results: CNS involvement was diagnosed by cerebrospinal fluid analysis (n = 6) and brain imaging (n = 5) in 11 patients at diagnosis, and four cases with CNS relapse were found. Thus, 15 patients had CNS involvement (15/46, 33%). The clinical characteristics were not different between patients with and without CNS involvement, but all patients with CNS involvement belonged to the high-risk group of CNS-International Prognostic Index (IPI). Thirty-one patients achieved a complete response (67%, 31/46) whereas eight patients showed disease progression and six patients died after the first or second cycle of R-CHOP. CNS-directed therapy such as high-dose methotrexate was combined with R-CHOP for patients with CNS involvement, and five patients were alive without relapse. The median overall survival of all patients was 45.0 months, and overall survival was not different according to the involvement of CNS. Conclusions: The treatment outcome of patients with the Asian variant of IVLBCL is still not satisfactory. The prediction of CNS involvement based on the clinical features including CNS-IPI score might not serve to identify patients at high risk of CNS involvement, either. Thus, more effective strategies for diagnosis and treatment should be developed.
Abstract
Background/Aims: There are limited data about the influence of the central nervous system (CNS) involvement on the prognosis for patients with the Asian variant of intravascular large B-cell lymphoma (IVLBCL). Methods: We analyzed 46 patients who were diagnosed with IVLBCL between 2001 and 2018. All patients were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Results: CNS involvement was diagnosed by cerebrospinal fluid analysis (n = 6) and brain imaging (n = 5) in 11 patients at diagnosis, and four cases with CNS relapse were found. Thus, 15 patients had CNS involvement (15/46, 33%). The clinical characteristics were not different between patients with and without CNS involvement, but all patients with CNS involvement belonged to the high-risk group of CNS-International Prognostic Index (IPI). Thirty-one patients achieved a complete response (67%, 31/46) whereas eight patients showed disease progression and six patients died after the first or second cycle of R-CHOP. CNS-directed therapy such as high-dose methotrexate was combined with R-CHOP for patients with CNS involvement, and five patients were alive without relapse. The median overall survival of all patients was 45.0 months, and overall survival was not different according to the involvement of CNS. Conclusions: The treatment outcome of patients with the Asian variant of IVLBCL is still not satisfactory. The prediction of CNS involvement based on the clinical features including CNS-IPI score might not serve to identify patients at high risk of CNS involvement, either. Thus, more effective strategies for diagnosis and treatment should be developed.
참고문헌 (21)
- Murase T, "An Asian variant of intravascular large B-cell lymphoma : clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome", Br J Haematol, 111, pp.826~834 (2000)
- Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
- Murase T, "Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5", Blood, 109, pp.478~485 (2007)
- Ponzoni M, "Definition, diagnosis, and management of intravascular large B-cell lymphoma : proposals and perspectives from an international consensus meeting", J Clin Oncol, 25, pp.3168~3173 (2007)
- Ferreri AJ, "Intravascular lymphoma:clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’", Br J Haematol, 127, pp.173~183 (2004)
- Ferreri AJ, "Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions", Haematologica, 92, pp.486~492 (2007)
- Rajyaguru DJ, "Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database", Leuk Lymphoma, 58, pp.1~9 (2017)
- Feugier P, "Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma : influence of rituximab", Ann Oncol, 15, pp.129~133 (2004)
- Bjorkholm M, "Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up", Ann Oncol, 18, pp.1085~1089 (2007)
- Boehme V, "CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)", Blood, 113, pp.3896~3902 (2009)
- Kim SJ, "Secondary central nervous system(CNS)involvement in patients with diffuse large B-cell lymphoma : a therapeutic dilemma", Ann Hematol, 90, pp.539~546 (2011)
- Schmitz N, "CNS International Prognostic Index : a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP", J Clin Oncol, 34, pp.3150~3156 (2016)
- Zhou Z, "An enhanced International Prognostic Index(NCCN-IPI)for patients with diffuse large B-cell lymphoma treated in the rituximab era", Blood, 123, pp.837~842 (2014)
- Cheson BD, "Revised response criteria for malignant lymphoma", J Clin Oncol, 25, pp.579~586 (2007)
- Su DW, "Asian-variant intravascular large B-cell lymphoma", Proc(Bayl Univ Med Cent), 30, pp.186~189 (2017)
- Schrader AMR, "High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma", Blood, 131, pp.2086~2089 (2018)
- Schmitz R, "Genetics and pathogenesis of diffuse large B-Cell lymphoma", N Engl J Med, 378, pp.1396~1407 (2018)
- Ferreri AJ, "The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B-cell lymphoma", Br J Haematol, 143, pp.253~257 (2008)
- Shimada K, "Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan", J Clin Oncol, 26, pp.3189~3195 (2008)
- Hong JY, "Clinical features and treatment outcomes of intravascular large B-cell lymphoma : a single-center experience in Korea", Acta Haematol, 131, pp.18~27 (2014)
- Meissner J, "Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma : the European Society for Blood and Marrow Transplantation experience", Bone Marrow Transplant, 52, pp.650~652 (2017)